COVID-19 Research Finds Rheumatic Disease Patients are at a Reduced Likelihood of Severe Outcomes Now vs. Early Days of Pandemic

TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), announced the publication of a COVID-19 study using real-world data (RWD) from the company’s network. The research, conducted by Massachusetts General Hospital and Harvard Medical School and published in The Lancet Rheumatology, found that individuals with autoimmune or immune-suppressing rheumatic diseases are less likely to have severe outcomes such as respiratory failure, renal failure, or death now compared to at the beginning of the pandemic.